K. Harrington, H.R. Kim, S. Salas, M. Oliva, R. Metcalf, M. Bernsdorf, J.W. Kim, E. Cohen, L. Siu, D. Rischin, L. Licitra, J. Vermorken, Q. T. Le, M. Tahara, J. Machiels, K. O'Hara, K. Pathiraja, B. Gumuscu, B. Bidadi, B. Burtness
{"title":"伦伐替尼±Pembrolizumab与化疗联合治疗铂类和免疫疗法后复发/转移性头颈部鳞状细胞癌(HNSCC):LEAP-009 2 期研究","authors":"K. Harrington, H.R. Kim, S. Salas, M. Oliva, R. Metcalf, M. Bernsdorf, J.W. Kim, E. Cohen, L. Siu, D. Rischin, L. Licitra, J. Vermorken, Q. T. Le, M. Tahara, J. Machiels, K. O'Hara, K. Pathiraja, B. Gumuscu, B. Bidadi, B. Burtness","doi":"10.1016/j.ijrobp.2024.01.095","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"14 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study\",\"authors\":\"K. Harrington, H.R. Kim, S. Salas, M. Oliva, R. Metcalf, M. Bernsdorf, J.W. Kim, E. Cohen, L. Siu, D. Rischin, L. Licitra, J. Vermorken, Q. T. Le, M. Tahara, J. Machiels, K. O'Hara, K. Pathiraja, B. Gumuscu, B. Bidadi, B. Burtness\",\"doi\":\"10.1016/j.ijrobp.2024.01.095\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14219,\"journal\":{\"name\":\"International Journal of Radiation Oncology*Biology*Physics\",\"volume\":\"14 4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology*Biology*Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.01.095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study